[10-Q] SELLAS Life Sciences Group, Inc. Quarterly Earnings Report

Q: What cash runway does SELLAS (SLS) report after Q2 2025?

The company reported $25.3 million of cash and stated these resources are not sufficient to fund planned operations for at least the next 12 months, creating substantial doubt about going concern.

Q: What were SELLAS's losses and cash usage for the six months ended June 30, 2025?

SELLAS reported a net loss of $12.4 million and $16.4 million net cash used in operating activities for the six months ended June 30, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

10-Q

Rhea-AI Filing Summary

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on immunotherapies for hematologic and solid tumors. For the six months ended June 30, 2025, the company reported a net loss of $12.4 million, used $16.4 million of cash in operations, and had $25.3 million of cash and cash equivalents with an accumulated deficit of $260.5 million. Management states these resources are not expected to be sufficient for at least the next 12 months, and substantial doubt about going concern exists.

Clinically, the company reported positive developments: the REGAL Phase 3 GPS study's independent data monitoring committee recommended continuation after its interim review and the final analysis will occur at 80 events. Separately, SLS009 met primary endpoints in a Phase 2 study with an overall response rate of 33% (40% at the 30 mg BIW dose) and particularly strong responses in patients with ASXL1 mutations (50% ORR)$23.1 million.

Positive

SLS009 Phase 2 met primary endpoints with an overall response rate of 33% across 54 evaluable patients
30 mg twice-weekly cohort achieved 40% ORR and 50% ORR in ASXL1-mutant patients, showing a predictive biomarker signal
Median overall survival ~8.8–8.9 months in key cohorts, exceeding historical benchmarks cited in the filing
FDA guidance to advance SLS009 into a randomized first-line aza/ven trial
REGAL (GPS) Phase 3 IDMC recommended continuation after interim review; final analysis to occur at 80 events
January 2025 registered direct offering provided approximately $23.1M in net proceeds, supporting near-term operations

Negative

Going concern: management expects cash will not be sufficient to fund planned operations for at least the next 12 months
Cash burn: used $16.4M in operating activities in the six months ended June 30, 2025, with a net loss of $12.4M
Accumulated deficit of $260.5M, reflecting sustained historical losses
Dependency on additional financing: company states it will require substantial additional funding and currently has no commitments
Arbitration with 3D Medicines introduces uncertainty over expected milestone payments and timing of potential receipts

Insights

TL;DR: Clinical progress increases asset value but near-term liquidity and a going-concern finding create urgent financing risk.

The 10-Q shows meaningful clinical catalysts that could drive value—an IDMC recommendation to continue REGAL and a positive Phase 2 readout for SLS009 with biomarker signals. However, the balance sheet and cash flow picture are constrained: $25.3M cash, $16.4M cash used in operations in six months, and management states cash is insufficient for the next 12 months. The January 2025 offering provided $23.1M net proceeds, which extends runway but does not eliminate financing risk. The binding arbitration with 3D Medicines introduces uncertainty around potential future milestone receipts. For investors, the timetable to meaningful de-risking depends on regulatory path and successful capital raises.

TL;DR: Positive clinical signals for SLS009 and continued REGAL progress materially de-risk the science and support development plans.

SLS009 demonstrated an overall response rate of 33% across 54 evaluable patients, with the 30 mg twice-weekly cohort achieving 40% ORR and 50% ORR in ASXL1-mutant patients; median overall survival in some cohorts reached ~8.8–8.9 months, outperforming historical benchmarks. The FDA's guidance to pursue a randomized first-line aza/ven study is a substantive regulatory endorsement of the development plan. REGAL's IDMC recommendation to continue after meeting the interim event threshold and an upcoming final analysis at 80 events are material milestones for GPS. These clinical developments increase the probability of future value creation, contingent on successful enrollment, final outcomes, and securing additional funding to execute next-phase trials.

08/12/2025 - 04:00 PM

0001390478December 312025Q2FALSExbrli:sharesiso4217:USDiso4217:USDxbrli:sharessls:segmentxbrli:pure00013904782025-01-012025-06-3000013904782025-08-1100013904782025-06-3000013904782024-12-3100013904782025-04-012025-06-3000013904782024-04-012024-06-3000013904782024-01-012024-06-300001390478us-gaap:CommonStockMember2025-03-310001390478us-gaap:AdditionalPaidInCapitalMember2025-03-310001390478us-gaap:RetainedEarningsMember2025-03-3100013904782025-03-310001390478sls:PreFundedWarrantsMemberus-gaap:CommonStockMember2025-04-012025-06-300001390478us-gaap:CommonStockMember2025-04-012025-06-300001390478us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001390478us-gaap:RetainedEarningsMember2025-04-012025-06-300001390478us-gaap:CommonStockMember2025-06-300001390478us-gaap:AdditionalPaidInCapitalMember2025-06-300001390478us-gaap:RetainedEarningsMember2025-06-300001390478us-gaap:CommonStockMember2024-12-310001390478us-gaap:AdditionalPaidInCapitalMember2024-12-310001390478us-gaap:RetainedEarningsMember2024-12-310001390478us-gaap:CommonStockMember2025-01-012025-06-300001390478us-gaap:AdditionalPaidInCapitalMember2025-01-012025-06-300001390478sls:PreFundedWarrantsMemberus-gaap:CommonStockMember2025-01-012025-06-300001390478sls:PreFundedWarrantsMember2025-01-012025-06-300001390478us-gaap:RetainedEarningsMember2025-01-012025-06-300001390478us-gaap:CommonStockMember2024-03-310001390478us-gaap:AdditionalPaidInCapitalMember2024-03-310001390478us-gaap:RetainedEarningsMember2024-03-3100013904782024-03-310001390478sls:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-04-012024-06-300001390478us-gaap:CommonStockMember2024-04-012024-06-300001390478us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001390478us-gaap:RetainedEarningsMember2024-04-012024-06-300001390478us-gaap:CommonStockMember2024-06-300001390478us-gaap:AdditionalPaidInCapitalMember2024-06-300001390478us-gaap:RetainedEarningsMember2024-06-3000013904782024-06-300001390478us-gaap:CommonStockMember2023-12-310001390478us-gaap:AdditionalPaidInCapitalMember2023-12-310001390478us-gaap:RetainedEarningsMember2023-12-3100013904782023-12-310001390478us-gaap:CommonStockMember2024-01-012024-06-300001390478us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001390478sls:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-01-012024-06-300001390478us-gaap:RetainedEarningsMember2024-01-012024-06-300001390478sls:January2025RegisteredDirectOfferingMember2025-01-292025-01-290001390478sls:PreFundedWarrantsMembersls:January2025RegisteredDirectOfferingMember2025-01-290001390478sls:PreFundedWarrantsMembersls:January2025RegisteredDirectOfferingMember2025-01-292025-01-290001390478sls:January2025RegisteredDirectOfferingMember2025-01-290001390478sls:EquityFinancings2022Through2024Member2025-01-012025-06-300001390478sls:EquityFinancings2022Through2024Member2025-06-300001390478sls:EquityFinancings2022Through2024Memberus-gaap:SubsequentEventMember2025-07-012025-08-120001390478sls:EquityFinancings2022Through2024Memberus-gaap:SubsequentEventMember2025-08-120001390478us-gaap:WarrantMember2025-01-012025-06-300001390478us-gaap:WarrantMember2024-01-012024-06-300001390478us-gaap:EmployeeStockOptionMember2025-01-012025-06-300001390478us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001390478us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-06-300001390478us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001390478sls:GenFleetTherapeuticsShanghaiIncMember2022-03-312022-03-310001390478sls:GenFleetTherapeuticsShanghaiIncMember2022-03-310001390478us-gaap:RestrictedStockUnitsRSUMember2025-06-300001390478sls:TwoThousandAndTwentyThreeAmendedAndRestatedEquityIncentivePlanMember2025-06-300001390478sls:A2021EmployeeStockPurchasePlanMember2025-06-300001390478sls:January2025RegisteredDirectOfferingMemberus-gaap:WarrantMember2024-12-310001390478sls:January2025RegisteredDirectOfferingMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:January2025RegisteredDirectOfferingMemberus-gaap:WarrantMember2025-06-300001390478sls:August2024RegisteredDirectOfferingMemberus-gaap:WarrantMember2024-12-310001390478sls:August2024RegisteredDirectOfferingMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:August2024RegisteredDirectOfferingMemberus-gaap:WarrantMember2025-06-300001390478sls:March2024RegisteredDirectOfferingMemberus-gaap:WarrantMember2024-12-310001390478sls:March2024RegisteredDirectOfferingMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:March2024RegisteredDirectOfferingMemberus-gaap:WarrantMember2025-06-300001390478sls:January2024OfferingMemberus-gaap:WarrantMember2024-12-310001390478sls:January2024OfferingMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:January2024OfferingMemberus-gaap:WarrantMember2025-06-300001390478sls:November2023RegisteredDirectMemberus-gaap:WarrantMember2024-12-310001390478sls:November2023RegisteredDirectMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:November2023RegisteredDirectMemberus-gaap:WarrantMember2025-06-300001390478sls:February2023OfferingMemberus-gaap:WarrantMember2024-12-310001390478sls:February2023OfferingMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:February2023OfferingMemberus-gaap:WarrantMember2025-06-300001390478sls:April2022OfferingMemberus-gaap:WarrantMember2024-12-310001390478sls:April2022OfferingMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:April2022OfferingMemberus-gaap:WarrantMember2025-06-300001390478sls:April2022OfferingModifiedWarrantsMemberus-gaap:WarrantMember2024-12-310001390478sls:April2022OfferingModifiedWarrantsMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:April2022OfferingModifiedWarrantsMemberus-gaap:WarrantMember2025-06-300001390478sls:PreFundedWarrantsMemberus-gaap:WarrantMember2024-12-310001390478sls:PreFundedWarrantsMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:PreFundedWarrantsMemberus-gaap:WarrantMember2025-06-300001390478sls:OtherWarrantIssuesMemberus-gaap:WarrantMember2024-12-310001390478sls:OtherWarrantIssuesMemberus-gaap:WarrantMember2025-01-012025-06-300001390478sls:OtherWarrantIssuesMemberus-gaap:WarrantMember2025-06-300001390478us-gaap:WarrantMember2024-12-310001390478us-gaap:WarrantMember2025-01-012025-06-300001390478us-gaap:WarrantMember2025-06-3000013904782020-12-012020-12-3100013904782020-12-3100013904782022-01-012022-03-310001390478srt:MaximumMembersls:TwoThousandAndSeventeenEquityIncentivePlanMember2017-12-290001390478sls:TwoThousandAndTwentyThreeAmendedAndRestatedEquityIncentivePlanMember2023-06-202023-06-200001390478sls:TwoThousandAndTwentyThreeAmendedAndRestatedEquityIncentivePlanMember2019-09-100001390478us-gaap:ResearchAndDevelopmentExpenseMember2025-04-012025-06-300001390478us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001390478us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-06-300001390478us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001390478us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-04-012025-06-300001390478us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300001390478us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-06-300001390478us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-300001390478srt:MinimumMember2025-01-012025-06-300001390478srt:MaximumMember2025-01-012025-06-300001390478us-gaap:EmployeeStockOptionMember2025-01-012025-06-300001390478us-gaap:RestrictedStockUnitsRSUMember2024-12-310001390478us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-06-300001390478sls:A2021EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2021-04-220001390478sls:A2021EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2021-04-222021-04-220001390478sls:A2021EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2025-06-172025-06-170001390478sls:A2021EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2025-01-012025-06-300001390478sls:A2021EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2025-06-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________

FORM 10-Q

________________________________


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-33958

SELLAS Life Sciences Group, Inc.

(Exact name of registrant as specified in its charter)


Delaware						20-8099512
(State of incorporation)						(I.R.S. Employer Identification No.)

7 Times Square, Suite 2503, New York, NY 10036

(646) 200-5278

(Address, including zip code, and telephone number, including

area code, of registrant's principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	SLS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter time that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ☐ Yes ☒ No

As of August 11, 2025, SELLAS Life Sciences Group, Inc. had outstanding 105,297,469 shares of common stock.

SELLAS LIFE SCIENCES GROUP, INC.

FORM 10-Q - Quarterly Report

For the Quarter Ended June 30, 2025

TABLE OF CONTENTS


		Page
	PART I - FINANCIAL INFORMATION
Item 1	Financial Statements	4
	Unaudited Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024	4
	Unaudited Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024	5
	Unaudited Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024	6
	Unaudited Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024	8
	Unaudited Notes to Consolidated Financial Statements	9
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3	Quantitative and Qualitative Disclosures About Market Risk	28
Item 4	Controls and Procedures	28
	PART II - OTHER INFORMATION
Item 1	Legal Proceedings	29
Item 1A	Risk Factors	29
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3	Defaults Upon Senior Securities	29
Item 4	Mine Safety Disclosures	29
Item 5	Other Information	29
Item 6	Exhibits	29

	Signatures

The names “SELLAS Life Sciences Group, Inc.,” “SELLAS,” the SELLAS logo, and other trademarks or service marks of SELLAS Life Sciences Group, Inc. appearing in this Quarterly Report on Form 10-Q are the property of SELLAS Life Sciences Group, Inc. Other trademarks, service marks or trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. We do not intend the use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of or by either of, these other companies.

Unless the context otherwise indicates, references in these notes to the “Company,” “we,” “us” or “our” refer to SELLAS Life Sciences Group, Inc. and its wholly owned subsidiaries.

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. Such forward-looking statements include the words "expect," "intend,” "plan," "believe," "project," "estimate,” "may,” "should," "anticipate," "will" and similar statements of a future or forward-looking nature identify forward-looking statements and include, without limitation, statements regarding:

•our future financial and business performance;

•strategic plans for our business and product candidates;

•our ability to develop or commercialize products;

•the expected results and timing of clinical trials and nonclinical studies;

•our ability to comply with the terms of our license agreements;

•developments and projections relating to our competitors and industry;

•our expectations regarding our ability to obtain, develop and maintain intellectual property protection and not infringe on the rights of others;

•our ability to retain and attract highly-skilled executive officers and employees;

•our future capital requirements and the timing of those requirements and sources and uses of cash;

•our ability to obtain funding for our operations; and

•changes in applicable laws or regulations.

These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statements, including the following:

•risks associated with preclinical or clinical development and trials;

•changes in the assumptions underlying our expectations regarding our future business or business model;

•our ability to develop, manufacture and commercialize product candidates;

•general economic, financial, legal, political and business conditions and changes in domestic and foreign markets;

•changes in applicable laws or regulations;

•the impact of natural disasters, including climate change, and the impact of health epidemics on our business;

•the size and growth potential of the markets for our products, and our ability to serve those markets;

•market acceptance of our planned products;

•our ability to raise capital;

•the possibility that we may be adversely affected by other economic, business, and/or competitive factors; and

•other risks and uncertainties set forth in this report in the section entitled “Risk Factors.”

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. There are or will be important factors that could cause actual results to differ materially from those indicated in these statements. These factors include, but are not limited to, those factors set forth in the sections captioned "Business – Overview,” “Risk Factors,” “Legal Proceedings,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission ("SEC") on March 20, 2025 ("2024 Annual Report") and in our other public filings with the SEC, all of which you should review carefully. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SELLAS LIFE SCIENCES GROUP, INC.

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

(Unaudited)


	June 30, 2025		December 31, 2024

ASSETS
Current assets:
Cash and cash equivalents	$	25,297	$	13,886
Restricted cash and cash equivalents	100		100
Prepaid expenses and other current assets	4,050		2,341
Total current assets	29,447		16,327
Operating lease right-of-use assets	683		925
Goodwill	1,914		1,914
Deposits and other assets	261		266
Total assets	$	32,305	$	19,432
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	3,336	$	3,500
Accrued expenses and other current liabilities	2,083		5,466
Operating lease liabilities	580		544
Total current liabilities	5,999		9,510
Operating lease liabilities, non-current	157		457
Total liabilities	6,156		9,967
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value; 350,000,000 shares authorized, 100,367,113 and 73,977,459 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	10		7
Additional paid-in capital	286,678		257,583
Accumulated deficit	(260,539)		(248,125)
Total stockholders’ equity	26,149		9,465
Total liabilities and stockholders’ equity	$	32,305	$	19,432

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except share and per share data)

(Unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024

Operating expenses:

Research and development	$	3,871	$	5,186	$	7,076	$	10,297
General and administrative	3,002		2,435		5,860		6,969
Total operating expenses	6,873		7,621		12,936		17,266
Loss from operations	(6,873)		(7,621)		(12,936)		(17,266)
Non-operating income:

Interest income	272		151		522		230
Total non-operating income	272		151		522		230
Net loss	$	(6,601)	$	(7,470)	$	(12,414)	$	(17,036)

Per share information:
Net loss per common share, basic and diluted	$	(0.07)	$	(0.13)	$	(0.13)	$	(0.33)
Weighted-average common shares outstanding, basic and diluted	98,558,567		57,630,506		93,189,273		51,221,752

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Amounts in thousands, except share amounts)

(Unaudited)



	Three Months Ended June 30, 2025
	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Total Stockholders' Equity
	Shares	Amount
Balance at March 31, 2025	90,896,125	$	9	$	281,688	$	(253,938)	$	27,759
Issuance of common stock upon the exercise of pre-funded warrants	3,485,040	—		—		—		—
Issuance of common stock upon the exercise of warrants	5,985,948	1		4,489		—		4,490
Stock-based compensation	—	—		501		—		501
Net loss	—	—		—		(6,601)		(6,601)
Balance at June 30, 2025	100,367,113	$	10	$	286,678	$	(260,539)	$	26,149


	Six Months Ended June 30, 2025
	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Total Stockholders' Equity
	Shares	Amount
Balance at December 31, 2024	73,977,459	$	7	$	257,583	$	(248,125)	$	9,465
Issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs	8,200,000	1		23,050		—		23,051
Issuance of common stock upon the exercise of pre-funded warrants	11,485,040	1		—		—		1
Issuance of common stock upon the exercise of warrants	6,655,181	1		4,991		—		4,992
Issuance of common stock under employee stock purchase plan	49,433	—		48		—		48
Stock-based compensation	—	—		1,006		—		1,006
Net loss	—	—		—		(12,414)		(12,414)
Balance at June 30, 2025	100,367,113	$	10	$	286,678	$	(260,539)	$	26,149

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Amounts in thousands, except share amounts)

(Unaudited)



	Three Months Ended June 30, 2024
	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Total Stockholders' Equity
	Shares	Amount
Balance at March 31, 2024	56,267,670	$	5	$	236,489	$	(226,810)	$	9,684
Issuance of common stock upon the exercise of pre-funded warrants	1,014,658	—		—		—		—
Issuance of common stock upon the exercise of warrants	472,600	—		365		—		365
Stock-based compensation	—	—		334		—		334
Net loss	—	—		—		(7,470)		(7,470)
Balance at June 30, 2024	57,754,928	$	5	$	237,188	$	(234,280)	$	2,913


	Six Months Ended June 30, 2024
	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Total Stockholders' Equity
	Shares	Amount
Balance at December 31, 2023	32,132,890	$	3	$	209,265	$	(217,244)	$	(7,976)
Issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs	21,130,000	2		26,658		—		26,660
Issuance of common stock upon the exercise of pre-funded warrants	3,899,316	—		—		—		—
Issuance of common stock upon the exercise of warrants	538,350			404				404
Issuance of common stock under employee stock purchase plan	54,372	—		51		—		51
Stock-based compensation	—	—		810		—		810
Net loss	—	—		—		(17,036)		(17,036)
Balance at June 30, 2024	57,754,928	$	5	$	237,188	$	(234,280)	$	2,913

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)


	Six Months Ended June 30,
	2025		2024
Cash flows from operating activities:
Net loss	$	(12,414)	$	(17,036)
Adjustment to reconcile net loss to net cash used in operating activities:
Non-cash stock-based compensation	1,006		810
Non-cash lease expense	296		276

Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,423)		(2,508)
Accounts payable	(164)		747
Accrued expenses and other current liabilities	(3,383)		(2,467)
Operating lease liabilities	(318)		(265)
Net cash used in operating activities	(16,400)		(20,443)



Cash flows from financing activities:
Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs	23,051		26,605

Proceeds from the exercise of common stock warrants	4,712		404
Proceeds from employee stock purchases	48		51
Net cash provided by financing activities	27,811		27,060
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents	11,411		6,617
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period	13,986		2,630
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period	$	25,397	$	9,247

Supplemental disclosure of cash flow information:
Cash received during the period for interest	$	522	$	230
Supplemental disclosure of non-cash investing and financing activities:

Proceeds from the exercise of common stock warrants in prepaid expenses and other assets	$	281	$	—
Offering expenses included in accounts payable and accrued expenses and other current liabilities	$	—	$	55
Warrant modifications recorded in stockholders' equity	$	—	$	725

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Description of Business

Overview

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S ("GPS"), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center ("MSK") and targets the Wilms Tumor 1 ("WT1") protein, which is present in an array of tumor types. SELLAS' second product candidate is SLS009 (tambiciclib), a small molecule, highly selective cyclin-dependent kinase 9 ("CDK9") inhibitor, which the Company licensed from GenFleet Therapeutics (Shanghai), Inc. ("GenFleet"), for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau and Taiwan ("SLS009 Territory"). Each of GPS and SLS009 has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications.

2. Liquidity and Going Concern

Since inception, the Company has incurred recurring losses and negative cash flows from operations and, as of June 30, 2025, has an accumulated deficit of $260.5 million. During the six months ended June 30, 2025, the Company incurred a net loss of $12.4 million, and used $16.4 million of cash in operations. The Company expects to continue to generate operating losses and negative cash flows from operations for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of the Company's product candidates and the achievement of a level of revenues adequate to support its cost structure.

On January 29, 2025, the Company consummated a registered direct offering (the "January 2025 Registered Direct Offering") with an institutional investor priced at-the-market under Nasdaq rules, pursuant to which the Company agreed to issue and sell 8,200,000 shares of common stock and 11,485,040 pre-funded warrants exercisable for shares of common stock, together with accompanying warrants to purchase up to 19,685,040 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined offering price of $1.27, and each pre-funded warrant and accompanying common warrant were sold together at a combined offering price of $1.2699. The common warrants have an exercise price of $1.20 per share. The net proceeds to the Company from the January 2025 Registered Direct Offering were approximately $23.1 million, after deducting the placement agents' fees and related offering expenses.

During the six months ended June 30, 2025, 6.7 million warrants issued in connection with previous equity financings between 2022 and 2024 were exercised at an exercise price of $0.75 per share for aggregate proceeds of approximately $5.0 million, $0.3 million of which was received subsequent to quarter-end. Subsequent to June 30, 2025, an additional 4.9 million warrants have been exercised, which were issued in connection with equity financings between 2022 and 2024, at an exercise price of $0.75 per share for additional proceeds of approximately $3.7 million.

In December 2020, the Company, together with its wholly-owned subsidiary, SLSG Limited, LLC, entered into an Exclusive License Agreement (the “3D Medicines Agreement”) with 3D Medicines Inc. ("3D Medicines"), pursuant to which the Company granted 3D Medicines a sublicensable, royalty-bearing license, under certain intellectual property owned or controlled by the Company, to develop, manufacture and have manufactured, and commercialize GPS and heptavalent GPS product candidates for all therapeutic and other diagnostic uses in mainland China, Hong Kong, Macau and Taiwan ("3DMed Territory"). As of June 30, 2025, the Company has received an aggregate of $10.5 million in upfront payments and certain technology transfer and regulatory milestones. There is a total of $191.5 million in potential future development, regulatory, and sales milestones, not including future royalties, that remains under the 3D Medicines Agreement, which milestones are all variable in nature and not under the Company's control. In December 2023, the Company commenced a binding arbitration proceeding against 3D Medicines, which involves, among other things, the trigger and payment of certain milestone payments due to the Company. See Note 5. Legal Proceedings.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

As of June 30, 2025, the Company had cash and cash equivalents of approximately $25.3 million and restricted cash and cash equivalents of $0.1 million. In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents will not be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements.

The Company will require substantial additional financing to commercially develop any current or future product candidates. If the Company is unable to obtain additional funding on a timely basis, it will be required to scale back its plans and place certain activities on hold. The Company currently does not have any commitments to obtain additional funds. The Company's management continues to evaluate different strategies to obtain the required funding for future operations. These strategies may include public and private placements of equity and/or debt securities, as well as payments from potential strategic research and development collaborations or licensing and/or marketing arrangements with pharmaceutical companies. Additionally, the Company continues to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to the Company's product candidates. There can be no assurance that these future funding efforts will be successful.

3. Basis of Presentation and Significant Accounting Policies

The Company's complete summary of significant accounting policies can be found in "Item 8. Financial Statements and Supplementary Data - Note 3. Basis of Presentation and Significant Accounting Policies" in the audited annual consolidated financial statements included in the 2024 Annual Report. The significant accounting policies summarized and included in the 2024 Annual Report have not materially changed, except as set forth below.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the ASC and Accounting Standards Updates ("ASUs") of the Financial Accounting Standards Board ("FASB").

Principles of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company, SLSG Limited, LLC, and Sellas Life Sciences Limited. The functional currency of the Company's non-U.S. operations is the U.S. dollar.

Unaudited Interim Results

These consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2024 Annual Report. The accompanying consolidated financial statements as of June 30, 2025 and for the three and six months ended June 30, 2025 and 2024, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2024 have been derived from the audited financial statements as of that date.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

allocate resources and in assessing performance. The Company's chief operating decision maker ("CODM") is the President & Chief Executive Officer.

The Company views its operations and manages its business as one operating segment, which includes all activities related to the development of novel therapeutics for a broad range of cancer indications. The determination of a single reportable segment is consistent with the consolidated financial information provided to the CODM. The CODM does not evaluate discrete financial information for each of the Company's clinical product candidates, and views and manages the Company's clinical programs as one consolidated segment for which all operations are centralized.

Segment profit or loss is measured as the Company's net loss as reported on the consolidated statement of operations. As the Company does not currently generate revenues, the CODM evaluates Company performance through the achievement of clinical development goals. The CODM also monitors the Company's cash and cash equivalents as reported on the consolidated balance sheet, net cash used in operations as reported on the consolidated statement of cash flows, and segment expense information in order to make operational decisions, allocate resources, and plan for future activities.

Segment expenses consist of the Company's functional expenses, research and development expenses and general and administrative expenses, as reported in the consolidated statement of operations. Other segment items included in the measure of segment net loss include non-operating income, which primarily relates to interest income. The measure of total segment assets is reported on the consolidated balance sheet as total assets.

The accounting policies of the Company's single reportable segment are the same as those for the consolidated financial statements described in this Note 3.

Fair Value of Financial Instruments

The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

As of June 30, 2025 and December 31, 2024, the carrying amounts of the Company’s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments and were categorized as Level 1. The Company did not transfer any financial instruments into or out of Level 3 classification during the six months ended June 30, 2025 or 2024.

Net Loss Per Share

Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

to the fact that, when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):


	Six Months Ended June 30,
	2025	2024
Common stock warrants	68,985	40,313
Stock options	2,654	1,953
Restricted stock units ("RSUs")	1,713	644
	73,352	42,910

Income Taxes

On July 4, 2025, the U.S. enacted a budget reconciliation package commonly referred to as the One Big Beautiful Bill Act of 2025 ("OBBBA"), which contains a broad range of tax reform provisions affecting businesses, including the permanent reinstatement of bonus depreciation on qualified property and full expensing of domestic research and experimental expenditures. The Company is currently evaluating the impact of the legislation on our consolidated financial statements.

Recent Accounting Standards Not Yet Adopted

In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by prescribing standard categories and greater disaggregation of information in the effective tax rate reconciliation, disclosure of income taxes paid disaggregated by jurisdiction, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated financial statements but does not expect a material impact upon adoption.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, which requires disclosure of disaggregated information about certain income statement expense line items in the notes to the financial statements on an interim and annual basis. ASU 2024-03 will be effective for the annual reporting periods in fiscal years beginning after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on the consolidated financial statements, but does not expect a material impact upon adoption.

4. Balance Sheet Accounts

Prepaid expenses and other current assets consist of the following (in thousands):


	June 30, 2025		December 31, 2024
Clinical trial costs	$	2,974	$	2,172
Insurance	648		39
Professional fees	147		130
Other	281		—
Prepaid expenses and other current assets	$	4,050	$	2,341

Accrued expenses and other current liabilities consist of the following (in thousands):

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)


	June 30, 2025		December 31, 2024
Clinical trial costs	$	760	$	3,339
Compensation and related benefits	1,036		1,777
Professional fees	265		308
Other	22		42
Accrued expenses and other current liabilities	$	2,083	$	5,466

5. Commitments and Contingencies

Leases

The Company has a non-cancelable operating lease for certain executive, administrative, and general business office space for its headquarters in New York, New York, which began on June 5, 2020, and was amended in February 2022 to add additional space. The Company assessed the lease amendment for the additional space and determined it should be accounted for as a separate contract. The leases will expire on September 30, 2026.

The weighted average discount rate of the Company's operating leases under FASB Topic ASC 842, Leases ("ASC 842") is approximately 13%. As of June 30, 2025, the leases have a remaining term of 1.3 years.

Rent expense related to the Company's operating leases was approximately $0.1 million for each of the three months ended June 30, 2025 and 2024, and $0.3 million for each of the six months ended June 30, 2025 and 2024.

The Company made cash payments related to its operating leases of approximately $0.2 million and $0.1 million for the three months ended June 30, 2025 and 2024, respectively, and $0.3 million for each of the six months ended June 30, 2025 and 2024.

Future minimum lease payments are as follows as of June 30, 2025 (in thousands):


Future minimum lease payments:
2025 (remaining)	$	317
2026	477
Total future minimum lease payments	794
Less: imputed interest	(57)
Current and non-current operating lease liabilities	$	737

Exclusive License Agreement with GenFleet Therapeutics (Shanghai) Inc.

On March 31, 2022, the Company entered into an exclusive license agreement with GenFleet pursuant to which GenFleet granted to the Company a sublicensable royalty-bearing license under certain of its intellectual property to develop, manufacture, and commercialize SLS009 for the treatment, diagnosis or prevention of disease in humans and animals in the SLS009 Territory.

In consideration for the exclusive license, the Company agreed to pay to GenFleet (i) an upfront and technology transfer fee of $10.0 million, all of which has been paid, (ii) development and regulatory milestone payments for up to three indications totaling up to $48.0 million in the aggregate upon the achievement of such milestones and (iii) sales milestone payments totaling up to $92.0 million in the aggregate upon the achievement of certain net sales thresholds in a given calendar year. The Company also agreed to pay GenFleet single-digit tiered royalties based upon a percentage of annual net sales, with the royalty rate escalating based on the level of annual net sales of SLS009 in the SLS009 Territory ranging from the low to high single digits.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

Legal Proceedings

From time to time, the Company may be subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred.

On December 20, 2023, the Company commenced a binding arbitration proceeding against 3D Medicines, administered by the Hong Kong International Arbitration Centre and governed by New York State law in accordance with the dispute resolution provisions in the 3D Medicines Agreement. The arbitration proceeding involves, among other things, the trigger and payment of the relevant milestone payments due to the Company as well as 3D Medicines’ failure to use commercially reasonable best efforts to develop GPS in the 3DMed Territory, and particularly in mainland China. See Part II, Item 1. Legal Proceedings. Except for this arbitration proceeding, as of June 30, 2025, there was no pending or threatened litigation.

6. Stockholders’ Equity

Preferred Stock

The Company has authorized up to 5,000,000 shares of preferred stock, $0.0001 par value per share, for issuance. There were no preferred shares outstanding as of June 30, 2025 and December 31, 2024.

Common Stock

The Company has authorized up to 350,000,000 shares of common stock, $0.0001 par value per share, for issuance.

As of June 30, 2025, the Company has shares of common stock reserved for future issuance as follows (in thousands):


Warrants outstanding			68,985
Stock options outstanding			2,654
RSUs outstanding			1,713
Shares reserved for future issuance under the 2023 Amended and Restated Equity Incentive Plan			1,356
Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan			830
Total common stock reserved for future issuance			75,538

7. Warrants to Acquire Shares of Common Stock

Warrants Outstanding

The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the six months ended June 30, 2025 (in thousands except per share data):

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)


Warrant Issuance	Outstanding, December 31, 2024	Granted	Exercised	Outstanding, June 30, 2025	Exercise Price per Share		Expiration
Warrants classified as equity:
January 2025 Registered Direct Offering	—	19,685	—	19,685	$	1.20	January 2030
August 2024 Registered Direct Offering	15,849	—	—	15,849	$	1.20	August 2029
March 2024 Registered Direct Offering	13,029	—	—	13,029	$	1.41	September 2029
January 2024 Offering	11,467	—	(206)	11,261	$	0.75	January 2029
November 2023 Registered Direct	3,652	—	(3,652)	—	$	0.75	January 2029
February 2023 Offering	6,994	—	(1,210)	5,784	$	0.75	February 2028
April 2022 Offering	766	—	—	766	$	5.40	April 2027
April 2022 Offering Modified Warrants	3,864	—	(1,587)	2,277	$	0.75	January 2029
Pre-Funded Warrants	—	11,485	(11,485)	—	$	0.0001	n/a
Other	334	—	—	334	$	3.88	July 2025 - August 2025
	55,955	31,170	(18,140)	68,985

Subsequent to June 30, 2025, an additional 4.9 million warrants issued in connection with equity financings between 2022 and 2024 were exercised at an exercise price of $0.75 per share for aggregate proceeds of approximately $3.7 million.

Warrants Classified as Equity

The warrants to acquire shares of common stock issued during the January 2025 Registered Direct Offering were recorded as equity upon issuance. During its evaluation of equity classification of these warrants, the Company considered the conditions as prescribed within ASC 815-40, Derivatives and Hedging, Contracts in an Entity’s own Equity (“ASC 815-40”). The conditions within ASC 815-40 are not subject to a probability assessment. The warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, Distinguishing Liabilities from Equity, as they are not puttable and do not represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC 815 but are eligible for the scope exception as they are indexed to the Company’s own stock and would be classified in permanent equity if freestanding.

8. Licensing Revenue

Exclusive License Agreement with 3D Medicines Inc.

In December 2020, the Company entered into the 3D Medicines Agreement pursuant to which the Company granted 3D Medicines a sublicensable royalty-bearing license under certain intellectual property owned or controlled by the Company, to develop, manufacture and have manufactured, and commercialize GPS and heptavalent GPS (referred to as GPS Plus) product candidates ("GPS Licensed Products") for all therapeutic and other diagnostic uses in the 3DMed Territory. In partial consideration for the rights granted by the Company, 3D Medicines agreed to pay the Company (i) a one-time upfront cash payment of $7.5 million, and (ii) milestone payments totaling up to $194.5 million in the aggregate upon the achievement of certain technology transfer, development and regulatory milestones, as well as sales milestones based on certain net sales thresholds of GPS Licensed Products in the 3DMed Territory in a given calendar year. 3D Medicines also agreed to pay tiered royalties based upon a percentage of annual net sales of GPS Licensed Products in the 3DMed Territory ranging from the high single digits to the low double digits.

Revenue Recognition

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

At inception, the Company evaluated the 3D Medicines Agreement under ASC Topic 606, Revenue From Contracts with Customers, and recognized an initial transaction price of $9.5 million, which included the $7.5 million upfront fee as well as $2.0 million in development milestones that were assessed to be probable of being achieved, while the remaining milestones were variable consideration subject to constraint at inception. In the first quarter of 2022, an additional $1.0 million in licensing revenue was recognized upon approval by China’s National Medical Products Administration (“NMPA”) for a small Phase 1 clinical trial investigating safety of GPS in China.

There is $191.5 million in potential future development, regulatory, and sales milestones, not including future royalties, remaining under the 3D Medicines Agreement as of June 30, 2025, which milestones are variable in nature and not under the Company's control. At the end of each reporting period, the Company reevaluates the probability of achievement of the future development, regulatory, and sales milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

For the sales-based royalties, the Company will recognize revenue when the related sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.

There was no licensing revenue recognized during the three and six months ended June 30, 2025 and 2024. There was no cost of licensing revenue recognized during the three and six months ended June 30, 2025 and 2024.

9. Stock-Based Compensation

2017 Equity Incentive Plan

On December 29, 2017, the 2017 Equity Incentive Plan was approved by the stockholders of the Company, which currently allows for issuance of up to approximately 17,000 shares of common stock underlying stock options granted prior to September 10, 2019. The 2017 Equity Incentive Plan was terminated upon the approval of the 2019 Equity Incentive Plan ("2019 Equity Plan") subject to outstanding stock options granted under the 2017 Equity Incentive Plan that remain exercisable through maturity for the Company's employees and directors.

2023 Amended and Restated Equity Incentive Plan

On September 10, 2019, the 2019 Equity Plan was approved by the stockholders of the Company. On June 20, 2023, an amendment to the 2019 Equity Plan was approved by the stockholders of the Company, which amended and restated the 2019 Equity Plan (as amended and restated, the "2023 Amended and Restated Equity Incentive Plan") to increase the number of shares of common stock authorized for issuance under the 2019 Equity Plan by 3,000,000 shares.

The 2023 Amended and Restated Equity Incentive Plan currently allows for issuance of up to approximately 6,036,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate.

As of June 30, 2025, approximately 1,356,000 shares of common stock were reserved for future grants under the 2023 Amended and Restated Equity Incentive Plan.

The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and six months ended June 30, 2025 and 2024, respectively (in thousands):

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Research and development	$	109	$	88	$	223	$	173
General and administrative	392		246		783		637
Total stock-based compensation	$	501	$	334	$	1,006	$	810

Options to Purchase Shares of Common Stock

The following table summarizes stock option activity of the Company for the six months ended June 30, 2025:


	Total Number of Shares (In Thousands)	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2024	1,837	$	4.18		$	301
Granted	817	0.95


Outstanding at June 30, 2025	2,654	$	3.19	7.95	$	2,056
Options exercisable at June 30, 2025	1,244	$	5.35	6.83	$	456

The aggregate intrinsic values of outstanding and exercisable stock options at June 30, 2025 were calculated based on the closing price of the Company’s common stock as reported on the Nasdaq Capital Market on June 30, 2025 of $2.19 per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company’s common stock and the exercise price of the underlying stock options.

The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The weighted average assumptions used during the three and six months ended June 30, 2025 and 2024, respectively, were as follows:


	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025		2024
Risk free interest rate	n/a	n/a	4.25	%	4.01	%
Volatility	n/a	n/a	122.43	%	130.41	%
Expected term (years)	n/a	n/a	6.17		6.19
Expected dividend yield	n/a	n/a	—	%	—	%

There were no options granted during each of the three months ended June 30, 2025 and 2024. The weighted-average grant date fair value of options granted during the six months ended June 30, 2025 and 2024 was $0.85 and $0.48, respectively.

The Company’s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected term assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company’s options of ten years with the average vesting term of four years for an average of approximately six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

As of June 30, 2025, there was $1.5 million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company’s operating expenses over a weighted-average period of 2.3 years.

Time-vested RSUs and RSUs with Performance Conditions

The following table summarizes RSU activity of the Company for the six months ended June 30, 2025:


	Shares (In Thousands)	Weighted Average Grant Date Fair Value
Unvested at December 31, 2024	472	$	1.46
Granted	1,241	$	0.96

Unvested at June 30, 2025	1,713	$	1.09

As of June 30, 2025, there was $1.4 million of unrecognized compensation cost related to outstanding RSUs that is expected to be recognized as a component of the Company's operating expenses over a weighted-average period of 2.1 years. No RSUs vested during the six months ended June 30, 2025.

2021 Employee Stock Purchase Plan

On April 22, 2021, the Board of Directors adopted the 2021 Employee Stock Purchase Plan ("2021 ESPP") which was approved by the Company's stockholders on June 8, 2021 and authorized the issuance of up to 300,000 shares of common stock pursuant to the 2021 ESPP. The 2021 ESPP allows employees to contribute up to 20% of their cash earnings, subject to a maximum of $25,000 per year under Internal Revenue Service rules, to be used to purchase shares of the Company’s common stock on semi-annual purchase dates. The 2021 ESPP allows eligible employees to purchase shares of common stock at a price per share equal to 85% of the lower of the fair market value of the common stock at the beginning or end of each six-month offering period during the term of the 2021 ESPP.

Amended and Restated 2021 Employee Stock Purchase Plan

On June 17, 2025, an amendment to the 2021 ESPP was approved by the stockholders of the Company, which amended and restated the 2021 ESPP (as amended and restated, the "Amended and Restated 2021 Employee Stock Purchase Plan") to increase the number of shares of common stock available for sale under the 2021 ESPP by 800,000.

During the six months ended June 30, 2025, 49,433 shares of common stock were purchased by employees under the 2021 ESPP for proceeds of approximately $0.1 million. There are currently 830,171 shares of common stock reserved for issuance under the Amended and Restated 2021 Employee Stock Purchase Plan as of June 30, 2025.

10. Subsequent Events

The Company evaluated all events or transactions that occurred after June 30, 2025 up through the date these consolidated financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition as of June 30, 2025 and results of operations for the three and six months ended June 30, 2025 and 2024, respectively, should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission, or SEC, on March 20, 2025, or our 2024 Annual Report, and our other public reports filed with the SEC.

Overview

We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Galinpepimut-S, or GPS: Highly Novel and Engineered Immunotherapy Targeting the WT1 Antigen

Our lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the WT1 protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers, and solid tumor indications.

We have an ongoing open label randomized Phase 3 clinical trial, the REGAL study, for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of second complete remission, or CR2, following successful completion of second-line antileukemic therapy. Patients are randomized to receive either GPS or best available treatment, or BAT. We expect this study will be used as the basis for submission of a Biologics License Application, or BLA, subject to a statistically significant and clinically meaningful trial outcome and agreement with the U.S. Food and Drug Administration, or the FDA. The primary endpoint of the REGAL study is overall survival, or OS. In March 2024, we announced the completion of enrollment of 126 patients at clinical sites in the U.S., Europe, and Asia with a planned interim safety, efficacy and futility analysis after 60 events (deaths). Study sites in the U.S. and Europe account for approximately, 75% of patients enrolled, with the U.S.-based sites representing the highest enrolling country. In December 2024, we announced that the pre-specified threshold of 60 events (deaths) per the protocol had been reached, triggering the interim analysis to be conducted by the Independent Data Monitoring Committee, or IDMC. In January 2025, we announced that the IDMC had completed pre-specified interim analysis of the REGAL study and had recommended that the study continue without modifications. In August 2025, we announced the completion of a periodic review by the IDMC and positive recommendation to continue the REGAL study without modification. The final analysis will be conducted once 80 events (deaths) are reached. We anticipate that 80 events will be reached this year. Because the final analysis is event driven, it is difficult to predict with any certainty and it may occur at a different time than currently expected.

In December 2020, we entered into an exclusive license agreement, or the 3D Medicines Agreement, with 3D Medicines Inc., or 3D Medicines, a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, for the development and commercialization of GPS, as well as the Company’s next generation heptavalent immunotherapeutic GPS+, which is at preclinical stage, across all therapeutic and diagnostic uses in mainland China, Hong Kong, Macau and Taiwan, which we refer to as Greater China. We have retained sole rights to GPS and GPS+ outside of Greater China. In November 2022, we announced that we had agreed with 3D Medicines for 3D Medicines to participate in the REGAL study through the inclusion of approximately 20 patients from mainland China. In December 2022, we entered into a Side Letter Agreement with 3D Medicines, or Side Letter, which together with the 3D Medicines Agreement, details the terms and conditions of 3D Medicines' participation in the REGAL study. Although the REGAL study has completed enrollment as announced in March 2024, in accordance with the predetermined statistical analysis plan, 3D Medicines may still enroll patients in mainland China. The timing of such participation and patient enrollment by 3D Medicines, if at all, cannot be predicted with certainty. As of March 15, 2025, we have received an aggregate of $10.5 million in upfront and milestone payments under the 3D Medicines Agreement and a total of $191.5 million in potential future development, regulatory and sales milestones, not including future royalties, remains under the license agreement,

which milestones are variable in nature and not under our control. In December 2023, we announced that we had commenced a binding arbitration proceeding against 3D Medicines to resolve a dispute regarding, among other things, the trigger and payment of relevant milestone payments due to us under the 3D Medicines Agreement. See Part II, Item 1., Legal Proceedings.

GPS was granted Orphan Drug Designations, or ODD, from the FDA, as well as orphan medicines designations from the European Medicines Agency, or EMA, in AML, malignant pleural mesothelioma, or MPM, and multiple myeloma, or MM, as well as Fast Track designations for AML, MPM, and MM from the FDA. In October 2024, the FDA granted Rare Pediatric Disease, or RPD, designation to GPS for the treatment of pediatric AML.

SLS009: Highly Selective Next Generation CDK9 Inhibitor

On March 31, 2022, we entered into an exclusive license agreement, or the GenFleet Agreement, with GenFleet Therapeutics (Shanghai), Inc., or GenFleet, a clinical-stage biotechnology company developing cutting-edge therapeutics in oncology and immunology, that grants rights to us for the development and commercialization of SLS009, a highly selective small molecule CDK9 inhibitor, across all therapeutic and diagnostic uses worldwide, except for Greater China.

CDK9 activity has been shown to correlate negatively with overall survival in a number of cancer types, including hematologic cancers, such as AML and lymphomas, as well as solid cancers, such as osteosarcoma, pediatric soft tissue sarcomas, melanoma, endometrial, lung, prostate, breast and ovarian. As demonstrated in preclinical and clinical data, to date, SLS009’s high selectivity has the potential to reduce toxicity as compared to older CDK9 inhibitors and other next-generation CDK9 inhibitors currently in clinical development and to potentially be more efficacious.

We completed a Phase 1 dose-escalating clinical trial in the United States and China for SLS009 in mid-2023 and reported positive safety and efficacy data for both patient cohorts, that is relapsed and/or refractory AML and refractory lymphoma. We also established in the trial a recommended Phase 2 dose, or RP2D, of 60 mg once weekly for AML and 100 mg once weekly for lymphomas.

In the second quarter of 2023, we commenced an open label, single arm, multi-center Phase 2a clinical trial with SLS009 in combination with venetoclax and azacitidine, or aza/ven, in patients with AML who failed or did not respond to treatment with venetoclax-based therapies. The trial is evaluating safety, tolerability, and efficacy at two dose levels of SLS009, 45 mg once weekly, and 60 mg once weekly or 30 mg twice a week, in combination with aza/ven. In addition to safety and tolerability of SLS009 in combination with aza/ven, the efficacy endpoints are complete response composite rate and duration of response. Additional endpoints include event free survival, overall survival, and pharmacokinetic and pharmacodynamic assessments.

In the fourth quarter of 2023, we completed enrollment in the 45 mg (safety) dose cohort in the Phase 2a study and reported positive initial topline data. At that time, we also commenced enrollment in the 60 mg dose cohort with patients randomized to one of two groups, 60 mg fixed dose once weekly or 30 mg fixed twice weekly. Each group was planned to enroll five to 10 patients. During the trial we identified 30 mg fixed twice weekly as our optimal dose level.

During the trial, we identified potential biomarkers currently undergoing testing as predictive markers in the most recent portion of the study. In May 2024, we announced additional preliminary data from the Phase 2a trial of SLS009 in r/r AML and successful filing of a provisional patent application around the ASXL1 mutation and SLS009, including all CDK9 inhibitor drugs. ASXL1 mutations are associated with poor prognosis in all myeloid diseases, owing to the reduced response to the current treatment options. We observed a high rate of responses in patients with myelodysplasia-related molecular mutations, or AML MR, as defined by the World Health Organization, and patients with the ASXL1 gene mutation accounted for the most responders across all dose cohorts. We expanded the ongoing study to include two additional cohorts, one with ASXL1 mutated AML patients and one with patients with myelodysplasia-related molecular abnormalities other than ASXL1 at the optimal dose level of 30 mg fixed twice weekly. In December 2024, we announced positive data from the first 3 cohorts in the Phase 2a trial.

In July 2025, we announced that the Phase 2 trial of SLS009 in r/r AML met all primary endpoints and received FDA guidance to advance our first-line therapy study. The overall response rate, or ORR, in 54 evaluable patients was 33% across all cohorts and dose levels, 40% for the 30 mg BIW dose level, and 44% in the 30 mg BIW dose among AML-Myelodysplasia-Related Changes, or AML MR, patients, all exceeding the pre-specified ORR threshold of 20%. The highest efficacy was observed among patients with ASXL1 mutations, with an ORR of 50% (9/18) at 30 mg BIW dose levels, and AML MR with Myelomonocytic/Myelomonoblastic, or M4/M5, patients with an

ORR of 50% (6/12). The median overall survival, or mOS, reached 8.9 months in patients with AML MR and 8.8 months in patients r/r to venetoclax-based regimens at a 30 mg BIW dose level, surpassing the historical benchmark of ~2.4 months. SLS009 was well-tolerated with no new safety signals observed. No dose-limiting toxicities were observed across all dose levels.

In addition, following a productive end of Phase 2 meeting, the FDA recommended that we proceed into a trial to include newly diagnosed, first-line AML patients eligible for aza/ven therapy, where the FDA noted clinical benefit might be greatest. The randomized 80-patient trial is currently in preparation and expected to begin enrollment by the first quarter of 2026. The trial will include two groups: predictive biomarker cohort (newly diagnosed patients unlikely to benefit from standard aza/ven therapy based on molecular profiling) and early resistance cohort (patients who initiate treatment with aza/ven, but demonstrate confirmed lack of any response after two treatment cycles).

In November 2024, we announced data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009 in response to solid cancers. SLS009 is also currently being evaluated in pediatric solid tumors and leukemia models through the NCI Pediatric Preclinical in Vivo Testing, or PIVOT, program. Studies are supported through cooperative agreement grants from the NCI to the PIVOT research centers performing the testing in pediatric tumor models and a centralized coordinating center.

In May 2025, we announced data for pediatric acute lymphoblastic leukemia, or ALL, patients derived xenografts, or PDX. The experiment conducted and funded by the National Institute of Health, or NIH, through PIVOT program included 27 patient-derived ALL tumors from pediatric patients. Tumors were xenografted in mice in two groups, vehicle control arm and SLS009 arm. Mice were treated with a fractionated dose once per week for six consecutive weeks. Treatment was well tolerated. For all models, median survival was approximately tripled in the SLS009 arm, compared to vehicle control arm. SLS009 demonstrated delayed progression in 25/27 (93%) models and more than two times longer time to progression in 15/27 (56%) of ALL models. In addition, there were complete responses, or CR, in two models and in one of the two models CR was maintained after the treatment had been completed until the end of the study (four months). Among seven KMT2A rearranged models, time to progression was extended in all seven models, and in six out of seven (86%) time to progression was more than doubled.

For SLS009, the FDA granted Orphan Drug Product designations in AML and peripheral T-cell lymphoma, or PTCL, and Fast Track designations for r/r AML and r/r PTCL. The FDA granted RPD designation to SLS009 for the treatment of pediatric acute lymphoblastic leukemia, or ALL, in June 2024 and the FDA granted RPD designation to SLS009 for the treatment of pediatric AML in July 2024. Also, the European Medicines Agency granted Orphan Drug Designation for SLS009 in AML and in PTCL in June 2024 and July 2024, respectively.

Components of Results of Operations

Research and Development

Research and development expense consists of expenses incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses include:

•expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials;

•manufacturing and clinical drug supply expenses;

•outsourced professional scientific development services;

•employee-related expenses, which include salaries, benefits and stock-based compensation;

•payments made under our license agreements, under which we acquired certain intellectual property;

•expenses relating to certain regulatory activities, including filing fees paid to regulatory agencies;

•laboratory materials and supplies used to support our research activities; and

•allocated expenses, utilities, and other facility-related costs.

The successful development of our current and future product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from, any current or future product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of our clinical trials, which vary significantly over the life of a project as a result of many factors, including:

•the number and geographical location of clinical sites included in the trials;

•the length of time required to enroll suitable patients;

•the number and geographical location of patients that ultimately participate in the trials;

•the number of doses patients receive;

•the duration of patient follow-up;

•the results of clinical trials;

•the expenses associated with manufacturing and clinical drug supply;

•the receipt of marketing approvals; and

•the commercialization of current and future product candidates.

Research and development activities are central to our business model. Oncology product candidates in the later stages of clinical development generally have higher development costs than those in the earlier stages of clinical development, primarily due to the increased size and duration of the later-stage clinical trials. We expect our research and development expenses to increase for the foreseeable future as we conduct and complete our ongoing early and late-stage clinical trials and initiate additional clinical trials.

Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or target indications or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

General and Administrative

General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions, including stock-based compensation, travel expenses and recruiting expenses, fees for outside legal counsel, amortization of contract acquisition costs (commissions), and director and officer insurance premiums. Other general and administrative expenses include facility related costs, patent filing and prosecution costs, professional fees for business development, accounting, consulting, legal and tax-related services associated with maintaining compliance with our Nasdaq listing and SEC reporting requirements, investor relations costs, and other expenses associated with being a public company.

If and when we believe that regulatory approval of a product candidate appears likely, we anticipate that an increase in general and administrative expenses will occur as a result of our preparation for commercial operations, particularly as it relates to the sales and marketing of such product candidate. Oncology product commercialization may take several years and millions of dollars in development costs.

Non-Operating Income

Non-operating income consists of interest income. Interest income primarily reflects interest earned from our cash and cash equivalents.

Critical Accounting Policies and Estimates

In the 2024 Annual Report, we disclosed our critical accounting policies and estimates upon which our consolidated financial statements are derived. There have been no material changes to these policies and estimates since December 31, 2024 that are not included in Note 3 of the accompanying consolidated financial statements for the three and six months ended June 30, 2025. Readers are encouraged to read the 2024 Annual Report in conjunction with this Quarterly Report on Form 10-Q.

Results of Operations for the Three and Six Months Ended June 30, 2025 and 2024

The following tables summarize our results of operations for the three and six months ended June 30, 2025 and 2024 (in thousands):


	Three Months Ended June 30,
	2025		2024		Change

Operating expenses:

Research and development	$	3,871	$	5,186	$	(1,315)
General and administrative	3,002		2,435		567
Total operating expenses	6,873		7,621		(748)
Operating loss	(6,873)		(7,621)		748
Non-operating income	272		151		121
Net loss	$	(6,601)	$	(7,470)	$	869


	Six Months Ended June 30,
	2025		2024		Change

Operating expenses:

Research and development	$	7,076	$	10,297	$	(3,221)
General and administrative	5,860		6,969		(1,109)
Total operating expenses	12,936		17,266		(4,330)
Operating loss	(12,936)		(17,266)		4,330
Non-operating income:	522		230		292
Net loss	$	(12,414)	$	(17,036)	$	4,622

Further analysis of the changes and trends in our operating results are discussed below.

Research and Development

Research and development expenses were $3.9 million for the three months ended June 30, 2025 compared to $5.2 million for the three months ended June 30, 2024.


	Three Months Ended June 30,
	2025		2024		Change
External clinical trial expenses	$	2,038	$	3,034	$	(996)
Employee related expenses	772		703		69
Stock-based compensation	109		88		21
Clinical and regulatory consulting	510		590		(80)
Manufacturing and clinical drug supply	285		622		(337)
Facilities and other	157		149		8
Total research and development expenses	$	3,871	$	5,186	$	(1,315)

The decrease in research and development expenses of approximately $1.3 million was primarily attributable to

•$1.0 million of decreased external clinical trial expenses primarily driven by the completion of enrollment in the REGAL study in the first quarter of 2024; and

•$0.3 million of decreased manufacturing costs and clinical drug supply purchases, which were each primarily driven by the completion of enrollment in the REGAL study in the first quarter of 2024.

Research and development expenses were $7.1 million for the six months ended June 30, 2025 compared to $10.3 million for the six months ended June 30, 2024.


	Six Months Ended June 30,
	2025		2024		$ change
External clinical trial expenses	$	3,725	$	5,991	$	(2,266)
Employee related expenses	1,560		1,447		113
Stock-based compensation	223		173		50
Clinical and regulatory consulting	889		1,159		(270)
Manufacturing and clinical drug supply	363		1,249		(886)
Facilities and other	316		278		38
Total research and development expenses	$	7,076	$	10,297	$	(3,221)

The decrease in research and development expenses of approximately $3.2 million was primarily attributable to the following:

•$2.3 million of decreased external clinical trial expenses primarily driven by the completion of enrollment in the REGAL study in the first quarter of 2024;

•$0.9 million of decreased manufacturing costs and clinical drug supply purchases primarily driven by the completion of enrollment in the REGAL study in the first quarter of 2024;

•$0.3 million of decreased clinical consultant costs primarily driven by the completion of enrollment in the REGAL study in the first quarter of 2024; partially offset by

•$0.3 million of de minimis increases to employee related expenses, stock-based compensation, and facilities and other research and development expenses combined.

We anticipate that our research and development expenses will increase in the future as we continue to prepare for a potential BLA filing for GPS following the upcoming final analysis of the REGAL study and proceed into a trial to include newly diagnosed, front-line AML patients for SLS009.

General and Administrative

General and administrative expenses were $3.0 million for the three months ended June 30, 2025 compared to $2.4 million for the three months ended June 30, 2024. The $0.6 million increase was primarily attributable to a $0.3 million increase in legal fees, a $0.2 million increase in personnel related expenses, which includes a $0.1 million increase in non-cash stock-based compensation expense, and a $0.1 million increase in outside services and public company costs.

General and administrative expenses were $5.9 million for the six months ended June 30, 2025 compared to $7.0 million for the six months ended June 30, 2024. The $1.1 million decrease was primarily attributable to a $1.1 million decrease in personnel related expenses driven by the recognition of a $1.1 million one-time severance charge during the prior period and a $0.1 million decrease in annual insurance premiums, which were partially offset by a $0.1 million increase in other general and administrative expenses.

Non-Operating Income

Non-operating income of $0.3 million and $0.2 million during the three months ended June 30, 2025 and 2024, respectively, and $0.5 million and $0.2 million during the six months ended June 30, 2025 and 2024, respectively, was related to interest income earned from our cash and cash equivalents.

Liquidity and Capital Resources

We did not generate any revenue from product sales during the three and six months ended June 30, 2025 and 2024. Through June 30, 2025, we have only generated licensing revenue from the 3D Medicines Agreement. Since inception, we have incurred net losses, used net cash in our operations, and have funded substantially all of our operations through proceeds of the sale of equity securities and convertible notes.

Sources of Liquidity

On January 29, 2025, we consummated a registered direct offering with an institutional investor priced at-the-market under Nasdaq rules, or the January 2025 Registered Direct Offering, pursuant to which we agreed to issue and sell 8,200,000 shares of common stock and 11,485,040 pre-funded warrants exercisable for shares of common stock, together with accompanying warrants to purchase up to 19,685,040 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined offering price of $1.27, and each pre-funded warrant and accompanying common warrant were sold together at a combined offering price of $1.2699. The common warrants have an exercise price of $1.20 per share. The net proceeds to us from the January 2025 Registered Direct Offering were approximately $23.1 million, after deducting the placement agents' fees and related offering expenses.

During the six months ended June 30, 2025, 6.7 million warrants issued in connection with previous equity financings between 2022 and 2024 were exercised at an exercise price of $0.75 per share for aggregate proceeds of approximately $5.0 million, $0.3 million of which was received subsequent to quarter-end. Subsequent to June 30, 2025, an additional 4.9 million warrants have been exercised at an exercise price of $0.75 per share for additional proceeds of approximately $3.7 million.

In December 2020, together with our wholly-owned subsidiary, SLSG Limited, LLC, we entered into the 3D Medicines Agreement pursuant to which we granted 3D Medicines a sublicensable royalty-bearing license under certain intellectual property owned or controlled by us, to develop, manufacture and have manufactured, and commercialize GPS and heptavalent GPS product candidates for all therapeutic and other diagnostic uses in the 3DMed Territory. To date, we have received $10.5 million in upfront payments and certain technology transfer and regulatory milestones. A total of $191.5 million in potential future development, regulatory, and sales milestones, not including future royalties, remains under the 3D Medicines Agreement as of June 30, 2025, which milestones are all variable in nature and not under our control. In December 2023, we commenced a binding arbitration proceeding against 3D Medicines, which involves, among other things, the trigger and payment of certain milestone payments due to us. See Part II, Item 1., Legal Proceedings.

Funding Requirements

As of June 30, 2025, we had an accumulated deficit of $260.5 million, cash and cash equivalents of $25.3 million and restricted cash and cash equivalents of $0.1 million. We expect that our cash and cash equivalents will not be sufficient to fund our current planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions give rise to a substantial doubt over our ability to continue as a going concern. This going concern assumption is based on management’s assessment of the sufficiency of our current and future sources of liquidity and whether it is probable we will be able to meet our obligations as they become due for at least one year from the date our consolidated financial statements are available to be issued, and if not, whether our liquidation is imminent.

Our consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. We anticipate incurring additional losses until such time, if ever, that we can generate significant sales of any current or future product candidates in development.

We will require substantial additional financing to develop any current or future product candidates. If we are unable to obtain additional funding on a timely basis, we will be required to scale back our plans and place certain activities on hold. We currently do not have any commitments to obtain additional funds. Our management continues to evaluate different strategies to obtain the required funding for future operations. These strategies may include public and private placements of equity and/or debt securities, as well as payments from potential strategic research and development collaborations or licensing and/or marketing arrangements with pharmaceutical companies. Additionally, we continue to pursue discussions with global and regional pharmaceutical companies for

licensing and/or co-development rights to our product candidates. There can be no assurance that these future funding efforts will be successful.

Our future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of any additional financings, (ii) our ability to complete revenue-generating partnerships with pharmaceutical and biotechnology companies, (iii) the success of our research and development activities, (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately, (v) regulatory approval and market acceptance of our product candidates.

Cash Flows

The following table summarizes our cash flows from operating, investing, and financing activities for the six months ended June 30, 2025 and 2024 (in thousands):


	Six Months Ended June 30,
	2025		2024
Net cash (used in) provided by:
Operating activities	$	(16,400)	$	(20,443)

Financing activities	27,811		27,060
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents	$	11,411	$	6,617

Net Cash Used in Operating Activities

Net cash used in operating activities of $16.4 million during the six months ended June 30, 2025 was primarily attributable to our net loss of $12.4 million and a net change in our operating assets and liabilities of approximately $5.3 million, which were partially offset by net non-cash charges of approximately $1.3 million. The net change in our operating assets and liabilities is primarily attributable to an increase in prepaid expenses and other assets of approximately $1.4 million, a decrease in accrued expenses and other current liabilities of approximately $3.4 million, a decrease in operating lease liabilities of approximately $0.3 million, and a decrease in accounts payable of approximately $0.2 million. Net non-cash charges were driven by $1.0 million in non-cash stock-based compensation expense and $0.3 million in non-cash lease expense.

Net cash used in operating activities of $20.4 million during the six months ended June 30, 2024 was primarily attributable to our net loss of $17.0 million and a net change in our operating assets and liabilities of approximately $4.5 million, which were partially offset by net non-cash charges of approximately $1.1 million. The net change in our operating assets and liabilities is primarily attributable to an increase in prepaid expenses and other assets of approximately $2.5 million, a decrease in accrued expenses and other current liabilities of approximately $2.5 million, and a decrease in operating lease liabilities of approximately $0.2 million, which were partially offset by an increase in accounts payable of $0.7 million. Net non-cash charges were driven by $0.8 million in non-cash stock-based compensation expense and $0.3 million in non-cash lease expense.

Net Cash Provided by Financing Activities

We generated $27.8 million in net cash from financing activities during the six months ended June 30, 2025, which was due to approximately $23.1 million in net proceeds from the January 2025 Registered Direct Offering and $4.7 million in proceeds from the exercise of warrants.

We generated $27.1 million in net cash from financing activities during the six months ended June 30, 2024, which was due to approximately $26.6 million in net proceeds from the January 2024 Offering and March 2024 Registered Direct Offering, $0.4 million in proceeds from the exercise of warrants, and $0.1 million from the purchase of shares of common stock by employees under the 2021 Employee Stock Purchase Plan.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet financing arrangements as of June 30, 2025.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, our principal executive officer and our principal financial officer (the “Certifying Officers”), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the “Exchange Act”), such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this Quarterly Report on Form 10-Q:

(a)our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and

(b)our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In December 2020, we entered into the 3D Medicines Agreement. In November 2022, we announced that we had agreed with 3D Medicines for 3D Medicines to participate in the REGAL study through the inclusion of approximately 20 patients from mainland China.

In accordance with the terms of the 3D Medicines Agreement and the Side Letter, we had expected that 3D Medicines would begin enrolling patients in mainland China in the REGAL study in the second half of 2023 and subsequently make two development milestone payments totaling $13.0 million. Patients were enrolled in the REGAL study in Taiwan, which is part of the 3DMed Territory, prior to the second half of 2023.

On December 20, 2023, we commenced a binding arbitration proceeding against 3D Medicines, administered by the Hong Kong International Arbitration Centre and governed by New York State law as per the 3D Medicines Agreement. The arbitration proceeding involves, among other things, the trigger and payment of the relevant milestone payments due to us as well as 3D Medicines’ failure to use commercially reasonable best efforts to develop GPS in the 3DMed Territory, and particularly in mainland China.

We have engaged an international law firm with expertise in mainland China to assist us with the arbitration proceeding. While we are unable at this time to predict with certainty the outcome of the arbitration proceeding, or the timing of the receipt of any milestone payments and other damages it is seeking in the arbitration proceeding, if at all, we believe that our claims are meritorious.

ITEM 1A. RISK FACTORS

Please refer to our note on forward-looking statements on page 2 of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in our 2024 Annual Report. The risks described in such 2024 Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, operating results and stock price.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

On June 17, 2025, we held our Annual Meeting of Stockholders, or the Annual Meeting. As previously reported in our Current Report on Form 8-K filed on June 18, 2025, at the Annual Meeting, our stockholders cast the greatest number of votes in favor of holding future non-binding advisory stockholder votes on executive officer compensation, or Say-on-Pay votes, every year. The Board has determined that, consistent with the vote of the Company's stockholders and the Board's recommendation in the Proxy Statement for the Annual Meeting, the Company will continue to hold future Say-on-Pay votes every year until the next required stockholder vote on the frequency of Say-on-Pay votes is presented to the stockholders.

None of our directors or officers have adopted, modified, or terminated any trading plans under Rule 10b5-1 of the Exchange Act or any similar arrangements during the three months ended June 30, 2025.

ITEM 6. EXHIBITS

Exhibit
#

Description

Form

Exhibit

Filing Date

3.1

Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.) amended as of December 27, 2017

10-K

3.1

April 13, 2018

3.2

Amended and Restated By-Laws of the Registrant

8-K

3.3

January 5, 2018

10.1

Amended and Restated 2021 Employee Stock Purchase Plan

31.1

Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**

31.2

Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**

32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ***

32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ***

101.INS

XBRL Instance Document.*

101.SCH

XBRL Taxonomy Extension Schema.*

101.CAL

XBRL Taxonomy Extension Calculation Linkbase.*

101.DEF

XBRL Taxonomy Extension Definition Linkbase.*

101.LAB

XBRL Taxonomy Extension Label Linkbase.*

101.PRE

XBRL Taxonomy Extension Presentation Linkbase.*


*			Indicates management contract or compensatory plans or arrangements.
**			Filed herewith
***			The certifications attached as Exhibit 32.1 and Exhibit 32.2 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			SELLAS Life Sciences Group, Inc.

			By:						/s/ Angelos M. Stergiou

									Angelos M. Stergiou, MD, ScD h.c.
									President and Chief Executive Officer
									(Principal Executive Officer)

									Date: August 12, 2025

			By:						/s/ John T. Burns

									John T. Burns, CPA
									Chief Financial Officer
									(Principal Financial and Principal Accounting Officer)

									Date: August 12, 2025

Source: View Original Filing on SEC EDGAR

FAQ

What cash runway does SELLAS (SLS) report after Q2 2025?

The company reported $25.3 million of cash and stated these resources are not sufficient to fund planned operations for at least the next 12 months, creating substantial doubt about going concern.

What were SELLAS's losses and cash usage for the six months ended June 30, 2025?

SELLAS reported a net loss of $12.4 million and $16.4 million net cash used in operating activities for the six months ended June 30, 2025.

What are the key clinical updates for SLS009 reported in this 10-Q?

SLS009 Phase 2 met primary endpoints with an overall response rate of 33% (40% at 30 mg BIW), 50% ORR in ASXL1-mutant patients, median OS ~8.8–8.9 months, and FDA guidance to advance a randomized first-line trial.

What is the status of the REGAL Phase 3 GPS study?

The Independent Data Monitoring Committee recommended continuing the REGAL study after interim analysis and the final analysis will occur at 80 events, expected this year.

What recent financing did SELLAS complete and how much was raised?

SELLAS completed a January 2025 registered direct offering that generated approximately $23.1 million in net proceeds; warrant exercises during the period added additional proceeds.

Is SELLAS involved in any material legal disputes?

Yes, SELLAS commenced binding arbitration against 3D Medicines regarding milestone triggers and related development obligations under their license agreement.

[10-Q] SELLAS Life Sciences Group, Inc. Quarterly Earnings Report

Insights

FAQ

What cash runway does SELLAS (SLS) report after Q2 2025?

What were SELLAS's losses and cash usage for the six months ended June 30, 2025?

What are the key clinical updates for SLS009 reported in this 10-Q?

What is the status of the REGAL Phase 3 GPS study?

What recent financing did SELLAS complete and how much was raised?

Is SELLAS involved in any material legal disputes?

NASDAQ:SLS

SLS Rankings

SLS Latest News

SLS Latest SEC Filings

SLS Stock Data

Trending News

[10-Q] SELLAS Life Sciences Group, Inc. Quarterly Earnings Report

Insights

Financial Analyst neutral

Biotechnology Industry Specialist positive

FAQ

What cash runway does SELLAS (SLS) report after Q2 2025?

What were SELLAS's losses and cash usage for the six months ended June 30, 2025?

What are the key clinical updates for SLS009 reported in this 10-Q?

What is the status of the REGAL Phase 3 GPS study?

What recent financing did SELLAS complete and how much was raised?

Is SELLAS involved in any material legal disputes?

NASDAQ:SLS

SLS Rankings

SLS Latest News

SLS Latest SEC Filings

SLS Stock Data